MY VIEW…THE ROLE OF NIVOLUMAB IN SECOND LINE
THERAPY… today….
These are exciting times in the treatment of NSCLC
Nivolumab has changed 2
nd
line NSCLC treatment paradigm….
after
many years “living” only with Docetaxel
Patient selection for IO is an urgent issue:
•
PD-L1 expression matters…it´s neither perfect…nor bad, although it´s not a simple
picture to select patients
•
We should focus part of the attention on the “negatives”
Low toxicity….
we need to be cautious
